337 related articles for article (PubMed ID: 25701988)
21. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
22. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
[No Abstract] [Full Text] [Related]
23. NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
Brawley OW; Cornelius LJ; Edwards LR; Gamble VN; Green BL; Inturrisi CE; James AH; Laraque D; Mendez MH; Montoya CJ; Pollock BH; Robinson L; Scholnik AP; Schori M
NIH Consens State Sci Statements; 2008 Feb 27-29; 25(1):1-30. PubMed ID: 18309362
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
25. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Brandow AM; Panepinto JA
Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
[TBL] [Abstract][Full Text] [Related]
26. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
27. Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa.
Galadanci NA; Kanter J
Lancet Haematol; 2024 Jun; 11(6):e393-e395. PubMed ID: 38701813
[No Abstract] [Full Text] [Related]
28. Hydroxyurea for sickle cell anemia.
Naina HV; Harris S
N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
[No Abstract] [Full Text] [Related]
29. Treatment adherence in patients with sickle cell anemia.
Drotar D
J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
[No Abstract] [Full Text] [Related]
30. Two assays to evaluate potential genotoxic effects of hydroxyurea in sickle cell disease patients.
RodrÃguez A; Kouegnigan L; Ferster A; Cotton F; Duez P
Hemoglobin; 2012; 36(6):545-54. PubMed ID: 23094637
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
32. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
33. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
[TBL] [Abstract][Full Text] [Related]
34. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
[TBL] [Abstract][Full Text] [Related]
35. Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease.
Mahadeo KM; Oyeku S; Taragin B; Rajpathak SN; Moody K; Santizo R; Driscoll MC
Am J Hematol; 2011 Sep; 86(9):806-8. PubMed ID: 21850660
[No Abstract] [Full Text] [Related]
36. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
Bartolucci P; de Montalembert M
Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
[No Abstract] [Full Text] [Related]
37. Long-term use of hydroxyurea for sickle cell anemia.
Lee DA; Mueller BU
JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
[No Abstract] [Full Text] [Related]
38. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
Adekile A; Menzel S; Gupta R; Al-Sharida S; Farag A; Haider M; Akbulut N; Mustafa N; Thein SL
Am J Hematol; 2015 Jul; 90(7):E138-9. PubMed ID: 25851995
[No Abstract] [Full Text] [Related]
39. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
O'branski EE; Ware RE; Prose NS; Kinney TR
J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea and new agents for the treatment of sickle cell disease.
Rodgers GP
Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
